HIRA decides Keytruda & Opdivo’s insurance benefits with anti-PD-L1 TPS

‘Tumor proportion score(TPS) of anti-PD-L1’ is set as an index to decide whether to accept the insurance benefits of immunotherapies to treat non-small cell lung cancer.

The health insurance benefits of MSD’s ‘Keytruda(generic name: pembrolizumab)’ and Ono Pharmaceutical’s Opdivo(generic name: nivolumab)’ were set to be available for patients with more than 50% and 10%, respectively, in the T...